vs
Apellis Pharmaceuticals, Inc.（APLS）与Protagonist Therapeutics, Inc（PTGX）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Protagonist Therapeutics, Inc的1.2倍（$199.9M vs $170.6M），Protagonist Therapeutics, Inc净利率更高（77.2% vs -29.5%，领先106.7%），Protagonist Therapeutics, Inc同比增速更快（184.4% vs -5.9%），Protagonist Therapeutics, Inc自由现金流更多（$182.8M vs $-14.3M）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Protagonist Therapeutics是一家临床阶段生物制药公司，专注于研发创新肽类靶向疗法，以满足胃肠道疾病、炎症性疾病及罕见病领域未被满足的医疗需求，核心候选产品覆盖炎症性肠病等慢性免疫相关适应症。
APLS vs PTGX — 直观对比
营收规模更大
APLS
是对方的1.2倍
$170.6M
营收增速更快
PTGX
高出190.3%
-5.9%
净利率更高
PTGX
高出106.7%
-29.5%
自由现金流更多
PTGX
多$197.1M
$-14.3M
损益表 — Q4 FY2025 vs Q4 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $170.6M |
| 净利润 | $-59.0M | $131.7M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 74.3% |
| 净利率 | -29.5% | 77.2% |
| 营收同比 | -5.9% | 184.4% |
| 净利润同比 | -62.2% | 381.7% |
| 每股收益（稀释后） | $-0.40 | $2.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPTGX
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | — | ||
| Q2 25 | $178.5M | — | ||
| Q1 25 | $166.8M | — | ||
| Q4 24 | $212.5M | $170.6M | ||
| Q3 24 | $196.8M | — | ||
| Q2 24 | $199.7M | — | ||
| Q1 24 | $172.3M | $255.0M |
净利润APLSPTGX
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $-42.2M | — | ||
| Q1 25 | $-92.2M | — | ||
| Q4 24 | $-36.4M | $131.7M | ||
| Q3 24 | $-57.4M | — | ||
| Q2 24 | $-37.7M | — | ||
| Q1 24 | $-66.4M | $207.3M |
营业利润率APLSPTGX
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | 74.3% | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — | ||
| Q1 24 | -36.0% | 80.9% |
净利率APLSPTGX
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | — | ||
| Q2 25 | -23.6% | — | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -17.1% | 77.2% | ||
| Q3 24 | -29.2% | — | ||
| Q2 24 | -18.9% | — | ||
| Q1 24 | -38.5% | 81.3% |
每股收益（稀释后）APLSPTGX
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.74 | — | ||
| Q4 24 | $-0.30 | $2.01 | ||
| Q3 24 | $-0.46 | — | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-0.54 | $3.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $418.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $675.3M |
| 总资产 | $1.1B | $744.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSPTGX
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $418.9M | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | $322.6M |
总债务APLSPTGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSPTGX
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | — | ||
| Q1 25 | $164.2M | — | ||
| Q4 24 | $228.5M | $675.3M | ||
| Q3 24 | $237.1M | — | ||
| Q2 24 | $264.3M | — | ||
| Q1 24 | $266.7M | $560.4M |
总资产APLSPTGX
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $821.4M | — | ||
| Q1 25 | $807.3M | — | ||
| Q4 24 | $885.1M | $744.7M | ||
| Q3 24 | $901.9M | — | ||
| Q2 24 | $904.5M | — | ||
| Q1 24 | $831.9M | $629.3M |
负债/权益比APLSPTGX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $184.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $182.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 107.1% |
| 资本支出强度资本支出/营收 | 0.1% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 1.40× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $101.7M |
8季度趋势，按日历期对齐
经营现金流APLSPTGX
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.4M | $184.2M | ||
| Q3 24 | $34.1M | — | ||
| Q2 24 | $-8.3M | — | ||
| Q1 24 | $-133.0M | $-27.4M |
自由现金流APLSPTGX
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | $182.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — | ||
| Q1 24 | $-133.3M | $-27.7M |
自由现金流率APLSPTGX
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | 107.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — | ||
| Q1 24 | -77.3% | -10.9% |
资本支出强度APLSPTGX
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 0.8% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSPTGX
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PTGX
暂无分部数据
